Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.69 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.69 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylamide SCHEMBL4363896 | 0.91 | MAPT (0.69) | MAPTCACNA1BAPBA1APPCYP3A4 | |
| Acrylamide SCHEMBL4363895 | 0.91 | MAPT (0.69) | MAPTCACNA1BAPBA1APPCYP3A4 | |
| SCHEMBL36140 | 0.89 | MAPT (0.69) | MAPTCACNA1BAPBA1APPCYP3A4 | |
| SCHEMBL6885967 | 0.89 | MAPT (0.69) | MAPTCACNA1BAPBA1APPCYP3A4 | |
| SCHEMBL36139 | 0.89 | MAPT (0.69) | MAPTCACNA1BAPBA1APPCYP3A4 | |
| SCHEMBL36375 | 0.89 | MAPT (0.69) | MAPTCACNA1BAPBA1APPCYP3A4 | |
| Ethylene SCHEMBL28241615 | 0.86 | MAPT (0.67) | MAPTCACNA1BAPBA1APPCYP3A4 | |
| SCHEMBL7809907 | 0.86 | MAPT (0.67) | MAPTCACNA1BAPBA1APPCYP3A4 | |
| SCHEMBL7809914 | 0.86 | MAPT (0.67) | MAPTCACNA1BAPBA1APPCYP3A4 | |
| SCHEMBL11245982 | 0.83 | MAPT (0.63) | MAPTCACNA1BAPBA1APPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107936294-B | A kind of N- cetyl maleamic acid-lanthanum (III)-shepardite compound | 西安科技大学 | 2019-10-08 | — | — | CN | claimed |
| CN-107936294-A | A kind of N cetyls maleamic acid lanthanum (III) shepardite compound | 西安科技大学 | 2018-04-20 | — | — | CN | claimed |
| US-4915102-A | Applying a film layer to the skin | BERTEK, INC. (US) | 1990-04-10 | — | — | US | claimed |
| US-4134815-A | Amphoteric composite resins and method of preparing same by polymerization of a two-phase dispersion of monomers | ICI AUSTRALIA LIMITED (AU) | 1979-01-16 | — | — | US | claimed |
| EP-3980006-A2 | TOPICAL TIME RELEASE DELIVERY USING LAYERED BIOPOLYMER | Diomics Corporation (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-113061290-B | Nitrogen heterocyclic ring rare earth stabilizer | 常州佑佳新材料科技有限公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-113061290-A | Nitrogen heterocyclic ring rare earth stabilizer | 常州佑佳新材料科技有限公司 | 2021-07-02 | — | — | CN | disclosed |
| EP-3116861-B1 | SMALL MOLECULES FOR INHIBITING MALE FERTILITY | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2020-12-16 | — | — | EP | disclosed |
| WO-2020247874-A2 | TOPICAL TIME RELEASE DELIVERY USING LAYERED BIOPOLYMER | DIOMICS CORPORATION (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200188177-A1 | DERMAL DEVICE FOR ADMINISTRATION OF ONE OR MORE ACTIVE AGENTS TO THE SKIN | MYLAN INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10632195-B2 | Pharmaceutical device for electric-field assisted administration of Tapentadol and method of administering Tapentadol with same | GRUENENTHAL GMBH (DE) | 2020-04-28 | — | — | US | disclosed |
| US-10472334-B2 | Small molecules for inhibiting male fertility | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-11-12 | — | — | US | disclosed |
| US-4915102-A | Applying a film layer to the skin | BERTEK, INC. (US) | 1990-04-10 | — | — | US | disclosed |
| EP-0356614-A2 | Hinged dermal applicator | MLI ACQUISITION CORP. II (US) | 1990-03-07 | — | — | EP | disclosed |
| US-4707495-A | PROSTAGLANDINS | ORTHO PHARMACEUTICAL (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0225044-A1 | Peptic ulcer treatment | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-06-10 | — | — | EP | disclosed |
| US-4666441-A | Multicompartmentalized transdermal patches | CIBA-GEIGY CORPORATION (US) | 1987-05-19 | — | — | US | disclosed |
| US-4573996-A | Device for the administration of an active agent to the skin or mucosa | JONERGIN, INC. (US) | 1986-03-04 | — | — | US | disclosed |
| EP-0008227-B1 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL ADMINISTRATION CONTAINING PROSTAGLANDINS | AMERICAN CYANAMID COMPANY (US) | 1983-04-27 | — | — | EP | disclosed |
| US-4254145-A | LOCALIZED VASOCILATION | AMERICAN CYANAMID COMPANY (US) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472334-B2 | Small molecules for inhibiting male fertility | ACR, SPAG5, NASP | MAPT 4237/4885CACNA1B 3099/4885APBA1 4054/4885 |
| US-10632195-B2 | Pharmaceutical device for electric-field assisted administration of Tapentadol and method of administering Tapentadol with same | SLC6A2, SLC9A2, ATP1A2 | MAPT 2499/4885CACNA1B 125/4885APBA1 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.